Clinical trials: Disease-Free Survival
Breast Cancer
Study to Evaluate Real-world Effectiveness With Palbociclib Plus Endocrine Therapy as First-line/Second-line Treatment for HR+/HER2- Advanced Breast Cancer in Japan
This is a retrospective, multicenter, observational study in Japan by medical record review of advanced breast cancer (ABC) patients who have received palbociclib plus endocrine therapy (ET) as first line or second line setting.
- Trial name
- NCT05399329
- Testing
- Palbociclib, Endocrine therapy
- Where
- 20 sites in Japan
- Volunteers
- 693 people
- Sponsor
- Pfizer
Progression-free Survival, Gastrointestinal Stromal Tumor
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
The R0 resection rate of gastrointestinal stromal tumor (GIST) with high recurrence risk was relatively low, and the relapse-free survival rate was relatively low, which needed to be further improved.
- Conditions
- Progression-free Survival, Gastrointestinal Stromal Tumor, Neoadjuvant
- Trial name
- ZJGIST-01 (NCT04933669)
- Testing
- Imatinib
- Where
- China
- Volunteers
- 122 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Colorectal Cancer
MOR-1 Expression in Colorectal Cancer and Disease-free Survival Relationship. Five-year Follow-up.
Colorectal cancer (CRC) is a global burden and one of the most frequent types of cancer. Colorectal cancer therapy is complex and surgery remains the cornerstone for its treatment, combined with chemotherapy and radiotherapy.
- Trial name
- MOROCCO (NCT03601351)
- Testing
- ELISA for MOR-1 expression
- Where
- Spain
- Volunteers
- 174 people
- Sponsor
- Hospital Universitario La Fe
Critical Illness, Mechanical Ventilation Complication
The PREDICT Study- a Registry in Critically Ill Patients to Determine Predictors of Disability Free Survival
As mortality from critical illness has reduced, the importance of measuring disabilities (cognitive, functional and psychological) in surviving critically ill patients has become more important.
- Conditions
- Critical Illness, Mechanical Ventilation Complication, Disabilities Multiple, Quality of Life
- Trial name
- PREDICT (NCT03226912)
- Where
- Australia
- Volunteers
- 500 people
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
Outcome Assessment, Cancer of Colon
Textbook Outcome in Colon Carcinoma
BACKGROUND: Textbook outcome (TO) is a multidimensional quality management tool that uses a set of traditional surgical measures to reflect an "ideal" surgical result for a particular pathology.
- Trial name
- NCT05675904
- Testing
- Colon oncological resection
- Where
- Spain
- Volunteers
- 564 people
- Sponsor
- Hospital General Universitario de Alicante
Solid Neoplasms, Non-Small Cell Lung Cancer
PET/CT-Based Intratumoral Heterogeneity and Multimodal Imaging for Tumor Diagnosis and Prognosis
Background \& Rationale: Intratumoral heterogeneity (ITH) is a recognized hallmark and critical driver of therapeutic resistance, rapid disease progression, and poor survival across solid malignancies, notably advanced…
- Trial name
- NCT07906158
- Testing
- This is an observational study with no intervention.
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Shengjing Hospital
Biliary Tract Neoplasms
Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers
As a result of our previous NCRN study (ABC-02) cisplatin and gemcitabine (CisGem) is likely to become the international standard of care for patients with advanced biliary tract cancer (submitted: ASCO 2009).
- Trial name
- ABC-03 (NCT00939848)
- Testing
- gemcitabine, cisplatin, cediranib
- Where
- 2 sites in United Kingdom
- Volunteers
- 124 people
- Sponsor
- University College, London
Diffuse Large B Cell Lymphoma
Impact of an APA Program on EFS in Patients With Diffuse Large-cell B Lymphoma Treated in 1st Line
Diffuse large B cell lymphoma is the most common histology of non-Hodgkin's malignant lymphomas (31% of lymphomas), with an incidence of between 15 and 20 new cases per year per 100,000 inhabitants in France.
- Trial name
- PHARAOM (NCT04670029)
- Testing
- Adapted physical activity
- Where
- 5 sites in France
- Volunteers
- 186 people
- Sponsor
- Weprom
Renal Cell Carcinoma
Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.
Non-interventional study. Data obtained by patient chart reviews. Retrospective analysis of progression free survival, time to treatment failure and overall survival in a national cohort of patients with metastatic renal cell…
- Trial name
- NCT01339962
- Testing
- Non-interventional
- Where
- Denmark
- Volunteers
- 1,073 people
- Sponsor
- Pfizer
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer
This single-arm study assessed the efficacy and safety of first-line treatment with Avastin (bevacizumab) in combination with taxane-based chemotherapy (paclitaxel and gemcitabine) in patients with HER-2 negative breast cancer.
- Trial name
- NCT00846027
- Testing
- Bevacizumab, Paclitaxel, Gemcitabine
- Where
- 23 sites in Spain
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
Wounds and Injuries, Wound Infection
Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
This study will evaluate the use of free autologous dermal fat grafting (also called free dermal fat autografting) to treat complex craniofacial wounds that have failed standard treatment and to understand how well these grafts…
- Conditions
- Wounds and Injuries, Wound Infection, Facial Bones Fracture, Soft Tissue Injuries
- Trial name
- FTFDT2 (NCT03880188)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dufresne, Craig, MD, PC
HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer
Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer
This phase III, double-blind, placebo-controlled multinational study will assess the combination everolimus, vinorelbine, and trastuzumab compared to the combination vinorelbine and trastuzumab with respect to progressive-free…
- Trial name
- BOLERO-3 (NCT01007942)
- Testing
- everolimus, vinorelbine, trastuzumab
- Where
- 161 sites in United States, Argentina and 19 more
- Volunteers
- 569 people
- Sponsor
- Novartis Pharmaceuticals
Circumferential Resection Margin, Intraoperative Perforation of Rectum
Surgery Without Neoadjuvant Chemoradiotherapy Compared With Neoadjuvant Chemoradiotherapy for Rectal Cancer With Negative Circumferential Resection Margin Based on MRI Assessment, a Perspective Multicenter Randomized Controlled Trial
For now, neoadjuvant chemoradiotherapy is routinely performed for T3N1-2M0 rectal cancer. However, there are lots of complications following neoadjuvant chemoradiotherapy, such as Wound-related complications, anastomotic leakage…
- Conditions
- Circumferential Resection Margin, Intraoperative Perforation of Rectum, Local Recurrence of Malignant Tumor of Rectum, Disease-free Survival
- Trial name
- SCRM-01 (NCT03504449)
- Testing
- neoadjuvant chemoradiotherapy
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Beijing Chao Yang Hospital
Breast Cancer
Overall Survival and Disease-free Survival in Breast Cancer Patients Under COS
The main objective of the study is to evaluate the overall survival and disease-free survival in breast cancer patients under 40 years old.
- Trial name
- NCT02745262
- Testing
- Collect retrospectively the follow-up data
- Volunteers
- 400 people
- Sponsor
- IVI Vigo
Nasopharyngeal Carcinoma
Maintenance Treatment of Apatinib in Nasopharyngeal Carcinoma
The study is to evaluate the efficacy and safety of Apatinib for later treatment of patients(after second-line treatment for locally recurrent or metastatic nasopharyngeal carcinoma), including overall survival (OS), distant…
- Trial name
- NCT03130270
- Testing
- Apatinib mesylate tablet
- Where
- 4 sites in China
- Volunteers
- 29 people
- Sponsor
- Guilin Medical University, China
Endometrial Cancer
Comparison of Five-year Survival and Disease-free Survival in Patients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy With and Without Uterine Manipulator
Comparison of five-year survival and disease-free survival in patients diagnosed with endometrium cancer who underwent total laparoscopic hysterectomy with and without a uterine manipulator
- Trial name
- NCT06307886
- Testing
- Patients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy With manipulator, lPatients Diagnosed With Endometrium Cancer Who Underwent Total Laparoscopic Hysterectomy without uterine manipulator
- Where
- Turkey (Türkiye)
- Volunteers
- 108 people
- Sponsor
- Gaziosmanpasa Research and Education Hospital
Overall Survival, Disease-free Survival
Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma
Thermal ablation has been recommended by worldwide guidelines as first-line treatment for hepatocellular carcinoma (HCC), while evidence regarding its efficacy for primary intrahepatic cholangiocarcinoma (iCCA) is lacking.
- Trial name
- MALRIC (NCT06462742)
- Testing
- Microwave ablation (MWA) versus Liver Resection (LR)
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chinese PLA General Hospital
Non-Small Cell Lung Cancer
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.
This single arm study in patients with advanced Stage IIIb/IV NSCLC who have progressive disease after deriving clinical benefit (defined as response or stable disease after 12 weeks) from second or third line Tarceva monotherapy…
- Trial name
- NCT00773383
- Testing
- RG1507, erlotinib [Tarceva]
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 35 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma (MM)
MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma
The purpose of this research is to learn whether using teclistamab and talquetamab at different time points will improve survival in participants with high-risk Multiple Myeloma (MM).
- Trial name
- NCT07029776
- Testing
- teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Arkansas
Sepsis, Delirium
The MENDS2 Study, Maximizing the Efficacy of Sedation and Reducing Neurological Dysfunction and Mortality in Septic Patients With Acute Respiratory Failure
Ventilated ICU patients frequently have sepsis and the majority have delirium, a form of brain dysfunction that is an independent predictor of increased risk of dying, length of stay, costs, and prolonged cognitive impairment in…
- Conditions
- Sepsis, Delirium, Impaired Cognition
- Trial name
- MENDS2 (NCT01739933)
- Testing
- Dexmedetomidine, Propofol
- Where
- 11 sites in United States
- Volunteers
- 438 people
- Sponsor
- Vanderbilt University Medical Center